L'intérêt à découvert pour Cabaletta Bio donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Cabaletta Bio. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Cabaletta Bio (NASDAQ:CABA) Stock, Rapport sur les intérêts à découvert

CABALETTA BIO INC

Cabaletta Bio

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

<p>Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) affirms FY2026 Adj EPS guidance from $12.60-$12.90 to $12.60-$12.90 vs $12.69 analyst estimate..</p>


News

Guidance

Constellation Brands Affirms FY2026 Adj EPS Guidance of $12.60-$12.90 vs $12.69 Est

<p><i>ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC</i><br /><br /><i>12-month landmark survival of 88% and mOS of 32 months</i></p>
<p>BOSTON, July 01, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=U6uZoiaYsN9XtZjW8KdVnHlrgRQAThJuaNXzmvQfRDT7p03ofum_3l56cvLb6Oo_K9BWGavjLtHwb3OdGUmh15kntbjvB2LfH98FVwP0XXRrotMkSJS3ZEeoga9tx-C66vQ7XfXQkufw1IfSY2s0ag97kHuBdgbRor2B1lwj3tJ2nCxTJhkKP6JfGOIo7BwwSw1W6qmMDVuMT7ETXAVIN29EUmGQRkT3sAH0UzSxu83wBMDW3KvhE_oeVXx8HIHmhm-CYhN2hMgRcc599LCSPg==">Cue Biopharma, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today provided an update on its most advanced clinical stage asset, CUE-101, representative of the CUE-100 series.</p>
<p>Dr. Dimitrios Colevas presented new data from the company's maturing Phase 1 trial evaluating CUE-101 in combination with KEYTRUDA&#xAE; (pembrolizumab) for patients with recurrent metastatic HPV+ head and neck squamous cell carcinoma (HNSCC). Data highlights include an overall response rate (ORR) of 50% (with 1 unconfirmed PR) in patients with combined positive score (CPS) &gt;1 and an ORR of 50% observed in patients with low CPS scores (1-19). This compares favorably to the historical ORR of 19% observed with pembrolizumab alone in the third-party KEYNOTE 048 trial. Notably, the 12-month overall survival (OS) of 88% in the Phase 1 trial represents a significant reduction in the risk of death (HR 0.23) compared to historical data from the KEYNOTE 048 study. The Kaplan-Meier (K-M) estimate for median overall survival (mOS) is currently 32 months.</p>


Cue Biopharma Issues Update On Its Clinical Stage Asset, CUE-101, Representative Of CUE-100 Series; Data Highlights Include ORR Of 50% In Treatment-Naive Patients With HPV+ R/M HNSCC

<p><a href="https://www.globenewswire.com/Tracker?data=Kwadq9hGybbR4rqgXHlCISdNA55RyVG0qFRoVl_IBiaRnnVDNG7A4aVakfQujHaoDE94q3YtHKHigI1AZlgg_vsFv7dSh5RORHYo4bYSOtBmEhHNkgcxHdcZGWkz82RX">Eos Energy Enterprises, Inc. (NASDAQ:</a><a href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) ("Eos" or the "Company"), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS) manufactured in the United States, today announced that it has received its second loan advance from the Department of Energy's (DOE) Loan Programs Office in the amount of $22.7 million. With this advance, the Company has fully drawn the maximum allowable amount under the first tranche of $90.9 million in connection with the completion of its first state-of-the-art manufacturing line.</p>
<p>The loan advance covers 80% of eligible costs, incurred as part of the Company's production expansion plans related to Project AMAZE. These funds support Eos' ongoing efforts to expand its operational capacity to meet growing customer demand and further its strategic growth objectives.</p>


Financing

EOSE

Eos Energy Draws Full $90.9M DOE Loan Tranche To Boost U.S. Zinc Battery Production

<p>Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) reported quarterly earnings of $3.22 per share which missed the analyst consensus estimate of $3.31 by 2.6 percent. This is a 9.8 percent decrease over earnings of $3.57 per share from the same period last year.  The company reported quarterly sales of $2.515 billion which missed the analyst consensus estimate of $2.554 billion by 1.52 percent.  This is a 5.52 percent decrease over sales of $2.662 billion the same period last year.</p>


Earnings

Earnings Misses

Constellation Brands Q1 Adj. EPS $3.22 Misses $3.31 Estimate, Sales $2.515B Miss $2.554B Estimate

VERO

Venus Concept Announces Exchanges $6.5M Of Subordinated Convertible Notes Held By Affiliates Of Madryn Asset Management, LP For 325,651 Shares Of Series Y Preferred Stock

<p>ArriVent BioPharma, Inc. ("ArriVent") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In addition, ArriVent expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total amount of common stock and shares of common stock underlying pre-funded warrants on the same terms and conditions. All of the securities are being offered by ArriVent.</p>
<p>Goldman Sachs &amp; Co. LLC, Citigroup and Guggenheim Securities are acting as joint book-running managers for the proposed offering.</p>


Offerings

AVBP

ArriVent Announces Proposed $75M Public Offering Of Common Stock

Management

ORKA

Oruka Therapeutics Promotes Laura Sandler To Chief Operating Officer

<p>Bank OZK (the &quot;Bank&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) announced its Board of Directors declared a quarterly cash dividend on the Bank&#39;s common stock of $0.44 per share, up $0.01, or 2.33% from the prior quarter. The common stock dividend is payable on July 18, 2025 to shareholders of record as of July 11, 2025. Bank OZK has increased its quarterly cash dividend on its common stock in each of the last sixty quarters.</p>


Dividends

Bank OZK Announces Increase To Quarterly Common Stock Dividend From $0.43 To $0.44 Per Share

<p>Financial giants have made a conspicuous bullish move on Chevron. Our analysis of options history for Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) revealed 10 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $1,268,015, and 5 were calls, valued at $217,310.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $115.0 to $165.0 for Chevron over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Chevron's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Chevron's whale trades within a strike price range from $115.0 to $165.0 in the last 30 days. </p>
<h3>Chevron Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400116_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$7.3</td>
<td>$7.2</td>
<td>$7.29</td>
<td>$140.00</td>
<td>$1.0M</td>
<td>1.8K</td>
<td>1.5K</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$5.75</td>
<td>$5.65</td>
<td>$5.75</td>
<td>$145.00</td>
<td>$57.5K</td>
<td>4.3K</td>
<td>114</td>
</tr>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$29.15</td>
<td>$28.0</td>
<td>$29.15</td>
<td>$165.00</td>
<td>$55.4K</td>
<td>52</td>
<td>19</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.45</td>
<td>$3.35</td>
<td>$3.45</td>
<td>$165.00</td>
<td>$51.7K</td>
<td>3.8K</td>
<td>210</td>
</tr>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$10.65</td>
<td>$10.35</td>
<td>$10.35</td>
<td>$130.00</td>
<td>$45.5K</td>
<td>1.0K</td>
<td>94</td>
</tr>
</tbody>
</table>
</p>
<h3>About Chevron</h3>
<p>Chevron is an integrated energy company with exploration, production, and refining operations worldwide. It is the second-largest oil company in the United States with production of 3.0 million of barrels of oil equivalent a day, including 7.7 million cubic feet a day of natural gas and 1.7 million of barrels of liquids a day. Production activities take place in North America, South America, Europe, Africa, Asia, and Australia. Its refineries are in the US and Asia for total refining capacity of 1.8 million barrels of oil a day. Proven reserves at year-end 2024 stood at 9.8 billion barrels of oil equivalent, including 5.1 billion barrels of liquids and 28.4 trillion cubic feet of natural gas.</p>
<p>In light of the recent options history for Chevron, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Chevron</h3>
<ul>
<li>Currently trading with a volume of 6,031,437, the CVX's price is up by 1.98%, now at $146.03. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 31 days.</li>
</ul>
<h3>What The Experts Say On Chevron</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $165.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Chevron with a target price of $165. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Chevron options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

Spotlight on Chevron: Analyzing the Surge in Options Activity

<p>Deep-pocketed investors have adopted a bullish approach towards Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ACHR usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 25 extraordinary options activities for Archer Aviation. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 40% leaning bullish and 40% bearish. Among these notable options, 2 are puts, totaling $397,000, and 23 are calls, amounting to $1,484,599.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $3.5 to $17.0 for Archer Aviation over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Archer Aviation's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Archer Aviation's significant trades, within a strike price range of $3.5 to $17.0, over the past month.</p>
<h3>Archer Aviation Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400111_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ACHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/08/25</td>
<td>$0.79</td>
<td>$0.78</td>
<td>$0.79</td>
<td>$10.00</td>
<td>$316.0K</td>
<td>5.0K</td>
<td>4.0K</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.1</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$4.00</td>
<td>$175.1K</td>
<td>4.0K</td>
<td>256</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$2.33</td>
<td>$2.29</td>
<td>$2.33</td>
<td>$8.00</td>
<td>$116.5K</td>
<td>460</td>
<td>2.5K</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$2.33</td>
<td>$2.28</td>
<td>$2.32</td>
<td>$8.00</td>
<td>$116.0K</td>
<td>460</td>
<td>2.0K</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$2.33</td>
<td>$2.28</td>
<td>$2.32</td>
<td>$8.00</td>
<td>$116.0K</td>
<td>460</td>
<td>2.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Archer Aviation</h3>
<p>Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.</p>
<h3>Current Position of Archer Aviation</h3>
<ul>
<li>Trading volume stands at 48,846,482, with ACHR's price down by -8.62%, positioned at $9.91.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 37 days.</li>
</ul>
<h3>What The Experts Say On Archer Aviation</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $14.67.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Archer Aviation, targeting a price of $13.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $13.<br />
&#x2A; Consistent in their evaluation, an analyst from HC Wainwright &amp; Co. keeps a Buy rating on Archer Aviation with a target price of $18. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Archer Aviation options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


ACHR

Spotlight on Archer Aviation: Analyzing the Surge in Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Seagate Tech Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with STX, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 32 uncommon options trades for Seagate Tech Hldgs.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 40% bullish and 46%, bearish.</p>
<p>Out of all of the special options we uncovered, 19 are puts, for a total amount of $1,163,980, and 13 are calls, for a total amount of $664,810.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $105.0 and $165.0 for Seagate Tech Hldgs, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Seagate Tech Hldgs's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Seagate Tech Hldgs's whale activity within a strike price range from $105.0 to $165.0 in the last 30 days. </p>
<h3>Seagate Tech Hldgs Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400105_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>STX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$35.3</td>
<td>$35.0</td>
<td>$35.0</td>
<td>$165.00</td>
<td>$175.0K</td>
<td align="right">0</td>
<td align="right">157</td>
</tr>
<tr>
<td>STX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$3.8</td>
<td>$3.5</td>
<td>$3.7</td>
<td>$145.00</td>
<td>$137.6K</td>
<td align="right">363</td>
<td align="right">505</td>
</tr>
<tr>
<td>STX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$35.3</td>
<td>$35.0</td>
<td>$35.0</td>
<td>$165.00</td>
<td>$136.5K</td>
<td align="right">0</td>
<td align="right">107</td>
</tr>
<tr>
<td>STX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$38.0</td>
<td>$37.3</td>
<td>$37.4</td>
<td>$165.00</td>
<td>$127.1K</td>
<td align="right">58</td>
<td align="right">136</td>
</tr>
<tr>
<td>STX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$35.1</td>
<td>$34.6</td>
<td>$34.6</td>
<td>$160.00</td>
<td>$89.9K</td>
<td align="right">20</td>
<td align="right">50</td>
</tr>
</tbody>
</table>
</p>
<h3>About Seagate Tech Hldgs</h3>
<p>Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.</p>
<p>Following our analysis of the options activities associated with Seagate Tech Hldgs, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Seagate Tech Hldgs</h3>
<ul>
<li>With a volume of 3,960,244, the price of STX is down -0.39% at $143.76. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>What Analysts Are Saying About Seagate Tech Hldgs</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $145.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Seagate Tech Hldgs with a target price of $145. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Seagate Tech Hldgs, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Seagate Tech Hldgs Unusual Options Activity For July 01

<p>Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 20 years by 13.87% on an annualized basis producing an average annual return of 22.35%. Currently, Regeneron Pharmaceuticals has a market capitalization of $56.34 billion. </p>
<p><strong>Buying $100 In REGN:</strong> If an investor had bought $100 of REGN stock 20 years ago, it would be worth <strong>$5,977.36</strong> today based on a price of $521.83 for REGN at the time of writing.</p>
<h3>Regeneron Pharmaceuticals's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400083_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

REGN

Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today

<p><strong>Citigroup's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) short percent of float has risen 3.59% since its last report. The company recently reported that it has <strong>32.21 million shares sold short</strong>, which is 1.73% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.12 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Citigroup Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400030_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Citigroup has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Citigroup's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Citigroup's peer group average for short interest as a percentage of float is 0.90%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Is Citigroup Gaining or Losing Market Support?

<p><strong>PotlatchDeltic's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NYSE">PCH</a>) short percent of float has fallen 9.92% since its last report. The company recently reported that it has <strong>1.20 million shares sold short</strong>, which is 2.18% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.56 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>PotlatchDeltic Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400024_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for PotlatchDeltic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing PotlatchDeltic's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, PotlatchDeltic's peer group average for short interest as a percentage of float is 5.20%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Peering Into PotlatchDeltic's Recent Short Interest

<p><strong>Northrop Grumman's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) short percent of float has fallen 17.33% since its last report. The company recently reported that it has <strong>2.40 million shares sold short</strong>, which is 1.67% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.13 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Northrop Grumman Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400018_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Northrop Grumman has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Northrop Grumman's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Northrop Grumman's peer group average for short interest as a percentage of float is 5.11%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


How Is The Market Feeling About Northrop Grumman?

<p>VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) ("VivoPower" or the "Company") announced today that it has received a letter from the Nasdaq Stock Market LLC ("Nasdaq") wherein, based on the Company's Form 6-K, dated June 26, 2025, Nasdaq has determined that the Company complies with the Listing Rule 5550(b)(1).</p>
<p>As previously disclosed, on January 3, 2025, the Company received a notification letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of US$2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market (the "Rule"). Following the successful the first phase of the previously announced US$121 million private placement of the Company's ordinary shares, from which the Company recognized US$60.5 million in gross proceeds, the Company has now satisfied the stockholders' equity requirement.</p>
<p>Nasdaq will continue to monitor the Company's ongoing compliance with the minimum stockholders' equity requirement and, if at the time of its next periodic report for the year ended June 30, 2025, the Company does not evidence compliance with the minimum stockholders' equity requirement, the Company may be subject to delisting. At that such time, Nasdaq staff will provide written notification to the Company, which it may then appeal the Nasdaq staff's determination to a Hearings Panel.</p>


VVPR

VivoPower Receives Letter Of Compliance With Nasdaq Listing Standard

Global

Economics

Reuters Cites Statement From Egypt's Petroleum Ministry Saying It Received Report From Oil And Gas Production Company Osoco About A Capsized Vessel In Gulf Of Suez

<p>In the preceding three months, 8 analysts have released ratings for 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $150.38, a high estimate of $170.00, and a low estimate of $100.00. Surpassing the previous average price target of $146.38, the current average has increased by 2.73%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751399250_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of 3M among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$167.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Underperform</td>
<td>$100.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$164.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$142.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$165.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 3M. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 3M compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of 3M's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of 3M's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MMM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on 3M analyst ratings.</strong></a></p>
<h2>Delving into 3M's Background</h2>
<p>3M, a multinational conglomerate founded in 1902, sells tens of thousands of products ranging from sponges to respirators. The firm is well known for its extensive research and development capabilities, and it is a pioneer in inventing new use cases for its proprietary technologies. 3M is organized across three business segments: safety and industrial (representing around 44% of revenue), transportation and electronics (36%), and consumer (20%). The firm recently spun off its healthcare business, now known as Solventum. Nearly half of 3M's revenue comes from outside the Americas.</p>
<h3>Breaking Down 3M's Financial Performance</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Challenges:</strong> 3M's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-1.03%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> 3M's net margin excels beyond industry benchmarks, reaching <strong>18.74%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>26.87%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> 3M's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.8%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> 3M's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>3.15</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Expert Outlook: 3M Through The Eyes Of 8 Analysts

<p>Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Frontier Group Holdings, revealing an average target of $5.78, a high estimate of $10.00, and a low estimate of $3.00. This current average represents a 34.17% decrease from the previous average price target of $8.78. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751399236_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive Frontier Group Holdings is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$4.75</td>
</tr>
<tr>
<td>Ravi Shanker</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Stephen Trent</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$7.25</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Duane Pfennigwerth</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Atul Maheswari</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$3.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Frontier Group Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Frontier Group Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into Frontier Group Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ULCC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Frontier Group Holdings analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Frontier Group Holdings: A Closer Look</h2>
<p>Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.</p>
<h3>Unraveling the Financial Story of Frontier Group Holdings</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Frontier Group Holdings displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>5.43%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Frontier Group Holdings's net margin is impressive, surpassing industry averages. With a net margin of <strong>-4.71%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Frontier Group Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-7.33%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Frontier Group Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-0.68%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>8.41</strong>, caution is advised due to increased financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ULCC

Demystifying Frontier Group Holdings: Insights From 9 Analyst Reviews

<p>Shares of <strong>Archer Aviation Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) are experiencing a pullback Tuesday after a marked rally last Thursday. Here&#8217;s what investors <a href="https://www.benzinga.com/quote/ACHR">need to know</a>.</p>
<p><strong>What To Know:</strong> The <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46125984/why-joby-and-archer-aviation-shares-are-soaring-thursday">initial surge</a>, which also boosted competitor <strong>Joby Aviation Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>), was fueled by encouraging comments from Acting FAA Administrator <strong>Chris Rocheleau</strong>.</p>
<p>Rocheleau <a href="https://x.com/FAA_Chris/status/1938290132525703308">affirmed</a> the agency&#8217;s commitment to safely integrate new electric vertical takeoff and landing (eVTOL) aircraft into the national airspace, a crucial step for the burgeoning electric taxi sector.</p>
<p>This statement was a <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46125984/why-joby-and-archer-aviation-shares-are-soaring-thursday">significant tailwind</a> for both companies, which are at the forefront of developing and commercializing eVTOL technology. Joby is developing a five-seat aircraft for a global passenger service, with backing from strategic partners like <strong>Toyota</strong> and <strong>Delta</strong>. </p>
<p>Similarly, Archer Aviation is <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45948701/archer-aviation-stock-rises-on-deal-to-deploy-midnight-aircraft-in-indonesia">deploying</a> its &#8220;Midnight&#8221; aircraft, a four-passenger vehicle, with support from <strong>United Airlines</strong> and automotive giant <strong>Stellantis</strong>.</p>
<p>Both companies aim to revolutionize urban transport by offering a quiet, emission-free alternative to ground-based traffic. For companies like Joby and Archer, regulatory approval is among the ultimate gatekeepers to commercial viability. </p>
<p>The FAA&#8217;s explicit support for creating a clear and safe pathway to integration significantly de-risks their business models. This signal of regulatory progress could be a major draw for investors, reducing uncertainty and boosting confidence in the future ability of these futuristic air taxis to generate revenue.</p>
<p><strong>Price Action:</strong> According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ACHR shares are trading lower by 8.6% to $9.92 Tuesday afternoon. The stock has a 52-week high of $13.92 and a 52-week low of $2.82.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/pressreleases/25/06/b46011077/archer-partners-with-jetex-to-integrate-global-infrastructure-portfolio-into-air-taxi-network">Archer Partners With Jetex to Integrate Global Infrastructure Portfolio Into Air Taxi Network</a></strong></p>
<h2 class="wp-block-heading">How To Buy ACHR Stock</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Archer Aviation&#8217;s case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p><em>Image: Shutterstock</em></p>


JOBY

Archer Aviation (ACHR) Stock Is Sliding: What's Going On?

Health Care

Press Releases

General

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

Comments

Cabaletta Bio

Intérêt court

Cabaletta Bio (NASDAQ:CABA) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL